

Blast email about PAR-20-314 for NCI grantees (October 2020)



Assay Validation of High-Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Reissue of PAR-18-310. Posted date: October 13, 2020;

Expiration date: October 11, 2023.

Application receipt dates: February 18, 2021; July 9, 2021; October 8, 2021; February 14, 2022; July 11, 2022; October 11, 2022; February 14, 2023; July 10, 2023; October 10, 2023, by 5:00 PM local time of applicant organization.

Contact: Dr. Tracy Lively, 240-276-5944, livelyt@mail.nih.gov